ORILISSA (elagolix) 

SELF ADMINISTRATION

Indications for Prior Authorization:

  • Indicated for the management of moderate to severe pain associated with endometriosis.

Prior Authorization Criteria:

  • Patient is 18 years of age or older, AND
  • Diagnosis of moderate to severe pain associated with endometriosis, AND
  • Patient has tried and failed NSAIDs and continuous hormonal contraceptives for the treatment of mild to moderate endometrial pain, AND
  • Patient has tried and failed a complete trial of gonadotropin-releasing hormone (GnRH) agonist therapy (e.g. leuprolide) for more severe pain, AND
  • Patient does not have a contraindication to therapy (e.g. pregnancy, osteoporosis, severe hepatic impairment, concomitant use of strong OATP 1B1 inhibitors [e.g. cyclosporine, gemfibrozil])

Renewal Criteria:

  • Medical record documentation of symptom improvement, AND
  • Current therapy on 150 mg daily dose, AND
  • The patient does not have a coexisting condition (e.g. dyspareunia or hepatic impairment)

Dosing:

  • Patients without a coexisting condition: 150 mg daily
    • Max treatment duration: 24 months
  • Patients with Dyspareunia: 200 mg twice daily
    • Max treatment duration: 6 months
  • Moderate Hepatic Impairment (Child-Pugh Class B): 150 mg daily
    • Max treatment duration: 6 months

Approval:

  • Initial: 6 months
  • Renewal: 6 months (for a total treatment duration of up to 24 months)

Last review date: May 30, 2019

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone